Image: The WristView MRI system (Photo courtesy of Aspect Imaging).
A novel hand and wrist imaging system has received CE Mark (Conformité Européenne) approval for the European market, and is now on sale in the European Economic Area (EEA).
The novel hand and wrist Magnetic Resonance Imaging (MRI) imaging system was developed by a life-science startup company, and previously received U.S. Food and Drug Administration (FDA) approval.
The WristView imaging was developed by Aspect Imaging (Tel Aviv, Israel). The company designs and develops compact MR imaging and Nuclear Magnetic Resonance (NMR) systems for preclinical and medical applications.
WristView does not require cooling systems, or a special shielding room, costs less, and requires less training than a full-body MRI scanner. WristView uses a 1-T permanent magnet, and is optimized for hand and wrist applications, in terms of its design and bore size. The system requires very little maintenance, and has an extremely low-level external magnetic field, allowing it to be used anywhere in a hospital or research center. The CE Mark now enables the company to sell the scanner in Australia, New Zealand, Eastern Europe, and some Asian countries.
Founder and CEO of Aspect Imaging, Uri Rapoport, said, “We are thrilled to bring our MR imaging solutions to a wider international audience. Europe makes up a large percentage of the global market for this product in particular, and we’re extremely excited to now have the ability to introduce our system there. We encourage all people suffering from rheumatoid arthritis and carpal tunnel syndrome to demand that their condition be diagnosed with MRI.”